Share Print Email. About the Thoracic Lung Cancer Treatment Center The Lowe Center for Thoracic Oncology treats lung cancer — non-small cell lung cancer, small cell lung cancer, and mesothelioma — and other cancers of organs within the chest. Information and Resources Becoming a Patient As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.
Support Services and Amenities We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences. View this slide presentation by Raymond Mak, MD, Dana-Farber Department of Radiation Oncology — including the role of radiation therapy in non-small cell and small cell lung cancers, conventional radiation therapy, stereotactic body radiation therapy, and palliative conventional radiation therapy.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Clin Cancer Res Dabrafenib plus trametinib in patients with previously untreated BRAF VE -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib ASCEND-5 : a randomised, controlled, open-label, phase 3 trial. JAMA ; Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Nat Commun ; Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Transl Med ; ra Nature ; Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet ; Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. The EGFR gene produces a protein that helps cells divide. Specific changes or a mutation in the genetic information causes abnormal cell division and can lead to lung cancer.
They may stop or "inhibit" the effect of the mutation in the EGFR gene. Food and Drug Administration for this disease. After the screening procedures confirm participation in the research study:. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Participants must have normal organ and marrow function as defined below:.
Participants must have biopsy tissue at time of diagnosis available and sufficient for targeted next-generation sequencing. The sequencing can be performed at a commercial vendor such as Foundation Medicine. The testing does not have to be completed prior to study enrollment. If the specimen is insufficient a repeat biopsy will need to be performed. Female patients: Must not be pregnant or breast-feeding.
Women of child-bearing potential must have a negative pregnancy test urine or serum prior to start of dosing or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:. Significant medical history or unstable medical comorbidities, including:. Try the modernized ClinicalTrials. Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Share Print Email.
Deep expertise in diagnosing and treating even the most complicated cases. Minimally-invasive surgical techniques with faster recovery time. Genetically-based personalized medicine for certain types of tumors. Access to the very latest therapies, including clinical trials. Timely diagnosis and treatment appointments within five business days or less.
A full range of resources and treatments for symptom management.
0コメント